A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TPN171H, a Novel Phosphodiesterase Type 5 Inhibitor, in Healthy Subjects.
Qian H, Chen Q, Liang L, Zou Y, Pu H, Xin L, Song R, Li T, Zhu H, Wang Y, Tian G, Shen J, Jiang H, Yu C, Wang Z, Jia J.
Qian H, et al. Among authors: chen q.
Drug Des Devel Ther. 2021 Jul 6;15:2947-2959. doi: 10.2147/DDDT.S308610. eCollection 2021.
Drug Des Devel Ther. 2021.
PMID: 34262260
Free PMC article.
Clinical Trial.